Literature DB >> 11279534

Pathogenesis of prion diseases: a progress report.

A Aguzzi1, F L Heppner.   

Abstract

Almost 20 years have passed since Stanley Prusiner proposed that the agent causing transmissible spongiform encephalopathies consists exclusively of a protein and termed it prion. A mixed balance can be drawn from the enormous research efforts that have gone into prion research during this time. On the negative side, the protein-only hypothesis has not been conclusively proven yet. On the positive side, our understanding of spongiform encephalopathies has experienced tremendous advances, mostly through human genetics, mouse transgenetics, and biophysical methods. Perhaps the most astonishing development is the realization that many human neurodegenerative diseases for which transmissibility has been more or less stringently excluded, may follow pathogenetic principles similar to those of prion diseases. Also, the hypothesis that prion-like phenomena may underlie certain non-genetic traits observed in yeast has resulted in the surprising recognition that the instructional self-propagating changes in protein conformation may be much more prevalent in nature than previously thought. The latter developments have been astonishingly successful, and one could now argue that the prion principle is much more solidly established in yeast than in mammals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11279534     DOI: 10.1038/sj.cdd.4400737

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  11 in total

1.  Conversion of bacterially expressed recombinant prion protein.

Authors:  Fei Wang; Xinhe Wang; Jiyan Ma
Journal:  Methods       Date:  2010-12-19       Impact factor: 3.608

2.  The quantification of prion gene expression in sheep using real-time RT-PCR.

Authors:  Cai-Xia Han; Hong-Xiang Liu; De-Ming Zhao
Journal:  Virus Genes       Date:  2006-12       Impact factor: 2.332

3.  Alterations in neuronal metabolism contribute to the pathogenesis of prion disease.

Authors:  Julie-Myrtille Bourgognon; Jereme G Spiers; Hannah Scheiblich; Alexey Antonov; Sophie J Bradley; Andrew B Tobin; Joern R Steinert
Journal:  Cell Death Differ       Date:  2018-06-18       Impact factor: 15.828

4.  A C-terminal membrane anchor affects the interactions of prion proteins with lipid membranes.

Authors:  Nam K Chu; Waheed Shabbir; Erin Bove-Fenderson; Can Araman; Rosa Lemmens-Gruber; David A Harris; Christian F W Becker
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

5.  Location of the cross-β structure in prion fibrils: A search by seeding and electron spin resonance spectroscopy.

Authors:  Brett K-Y Chu; Ruei-Fong Tsai; Chien-Lun Hung; Yun-Hsuan Kuo; Eric H-L Chen; Yun-Wei Chiang; Sunney I Chan; Rita P-Y Chen
Journal:  Protein Sci       Date:  2022-06       Impact factor: 6.993

6.  Biochemical aspects of dementias.

Authors:  Christoph Hock
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

Review 7.  The Cellular Prion Protein: A Promising Therapeutic Target for Cancer.

Authors:  Gyeongyun Go; Sang Hun Lee
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

Review 8.  Current concepts and controversies in prion immunopathology.

Authors:  Mathias Heikenwalder; Marco Prinz; Frank L Heppner; Adriano Aguzzi
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866

9.  Whole Blood Gene Expression Profiling in Preclinical and Clinical Cattle Infected with Atypical Bovine Spongiform Encephalopathy.

Authors:  Elena Xerxa; Maura Barbisin; Maria Novella Chieppa; Helena Krmac; Elena Vallino Costassa; Paolo Vatta; Marion Simmons; Maria Caramelli; Cristina Casalone; Cristiano Corona; Giuseppe Legname
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

Review 10.  Prion protein-Semisynthetic prion protein (PrP) variants with posttranslational modifications.

Authors:  Stefanie Hackl; Christian F W Becker
Journal:  J Pept Sci       Date:  2019-10       Impact factor: 1.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.